Kite adds promis­ing leukemia re­spons­es in small CAR-T stud­ies, then fires the start­ing gun on its rolling sub­mis­sion

Kite Phar­ma­ceu­ti­cals $KITE has lined up a fresh batch of pos­i­tive ef­fi­ca­cy da­ta for its lead CAR-T for ad­vanced cas­es of acute lym­phoblas­tic leukemia at ASH. And then lat­er Sun­day evening the biotech added that it has launched its rolling sub­mis­sion for a first ap­proval.

In­ves­ti­ga­tors turned up at the big ASH meet­ing to say that the drug spurred a com­plete re­mis­sion in 9 of 11 evalu­able pa­tients — 82% — en­rolled in the ZU­MA-3 and ZU­MA-4 Phase I stud­ies for ALL in a pre­lim­i­nary re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER